First Tracks Biotherapeutics, Inc. Ordinary Shares When-Issued (NASDAQ:TRAXV) — Stock Price

$17.66 USD
▲ 3.55% today

First Tracks Biotherapeutics, Inc. Ordinary Shares When-Issued (NASDAQ:TRAXV) is currently trading at $17.66 USD, up 3.55% today. Over the past 52 weeks, shares have ranged between $15.33 and $25.40. This page tracks First Tracks Biotherapeutics, Inc. Ordinary Shares When-Issued's live share price on the NASDAQ exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. For company valuation and market capitalisation context, see market cap of First Tracks Biotherapeutics, Inc. Ordin.

First Tracks Biotherapeutics, Inc. Ordinary Shares When-Issued (TRAXV) Stock Price Chart — Daily History & Trading Volume

The chart below tracks First Tracks Biotherapeutics, Inc. Ordinary Shares When-Issued's daily closing share price and trading volume on the NASDAQ exchange over the past year, giving a clear view of recent price momentum and liquidity.

First Tracks Biotherapeutics, Inc. Ordinary Shares When-Issued Income Statement — Revenue, Profit & Earnings by Year

First Tracks Biotherapeutics, Inc. Ordinary Shares When-Issued's annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.

Fiscal Year 20242023
Total Revenue $0.00 $0.00
Cost of Revenue — —
Gross Profit — —
Research & Development $152.34 Million $97.59 Million
SG&A $28.76 Million $20.87 Million
Total Operating Expenses $181.10 Million $118.46 Million
Operating Income $-181.10 Million $-118.46 Million
EBITDA — —
EBIT — —
Interest Expense — —
Income Before Tax $-163.71 Million $-106.15 Million
Income Tax Expense — —
Net Income $-163.71 Million $-106.15 Million

First Tracks Biotherapeutics, Inc. Ordinary Shares When-Issued Balance Sheet — Assets, Liabilities & Shareholder Equity

The balance sheet below summarizes First Tracks Biotherapeutics, Inc. Ordinary Shares When-Issued's financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.

Fiscal Year 20242023
Total Assets $441.89 Million $444.11 Million
Total Current Assets $389.93 Million $398.56 Million
Cash & Equivalents — —
Short-term Investments $262.29 Million $354.94 Million
Net Receivables — —
Inventory — —
Property, Plant & Equipment — —
Goodwill — —
Total Liabilities $50.30 Million $34.26 Million
Total Current Liabilities $36.18 Million $18.22 Million
Long-term Debt — —
Net Debt — —
Total Stockholder Equity $391.60 Million $409.85 Million
Retained Earnings — —

First Tracks Biotherapeutics, Inc. Ordinary Shares When-Issued Cash Flow Statement — Operating, Investing & Financing Activities

This cash flow statement breaks down how First Tracks Biotherapeutics, Inc. Ordinary Shares When-Issued generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.

Fiscal Year 20242023
Operating Cash Flow $-125.81 Million $-93.00 Million
Capital Expenditures $358.00K $807.00K
Free Cash Flow $-126.16 Million $-93.81 Million
Investing Cash Flow — —
Financing Cash Flow $117.52 Million $-87.09 Million
Dividends Paid — —
Stock-Based Compensation $26.83 Million $18.39 Million
Depreciation $2.40 Million $2.38 Million
Change in Cash $87.11 Million $-35.34 Million

First Tracks Biotherapeutics, Inc. Ordinary Shares When-Issued Earnings History — EPS Actual vs. Analyst Estimates

Track First Tracks Biotherapeutics, Inc. Ordinary Shares When-Issued's quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.

Earnings history is not currently available for First Tracks Biotherapeutics, Inc. Ordinary Shares When-Issued.